Spark Therapeutics, Inc. (NASDAQ:ONCE) had its price target reduced by investment analysts at Cantor Fitzgerald from $105.00 to $94.00 in a report issued on Friday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 9.90% from the company’s current price.

Several other analysts have also weighed in on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Cowen and Company reaffirmed a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $95.00 price objective (up previously from $85.00) on shares of Spark Therapeutics in a report on Monday, September 25th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $111.00 price objective on shares of Spark Therapeutics in a report on Friday, October 6th. Finally, Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company’s stock. Spark Therapeutics presently has an average rating of “Buy” and an average price target of $90.47.

Spark Therapeutics (NASDAQ ONCE) opened at 85.53 on Friday. The stock’s 50 day moving average price is $85.85 and its 200 day moving average price is $85.85. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $91.75. The company’s market capitalization is $2.67 billion.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. During the same period last year, the company earned ($1.04) EPS. The business’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, equities research analysts anticipate that Spark Therapeutics will post ($7.59) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Spark Therapeutics, Inc. (ONCE) Price Target Lowered to $94.00 at Cantor Fitzgerald” was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/10/16/spark-therapeutics-inc-once-pt-lowered-to-94-00-at-cantor-fitzgerald.html.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 28,650 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $80.01, for a total value of $2,292,286.50. Following the transaction, the chief executive officer now directly owns 258,650 shares of the company’s stock, valued at $20,694,586.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total transaction of $430,800.00. Following the completion of the transaction, the insider now directly owns 215,000 shares in the company, valued at $18,524,400. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,333,195 shares of company stock worth $109,070,506. Insiders own 7.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Balyasny Asset Management LLC boosted its stake in Spark Therapeutics by 104.8% in the second quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock valued at $3,549,000 after acquiring an additional 30,400 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Spark Therapeutics by 8.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 94,920 shares of the biotechnology company’s stock valued at $5,671,000 after acquiring an additional 7,169 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Spark Therapeutics by 1.2% in the second quarter. Victory Capital Management Inc. now owns 417,410 shares of the biotechnology company’s stock valued at $24,936,000 after acquiring an additional 4,750 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Spark Therapeutics by 10.9% in the first quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock valued at $5,923,000 after acquiring an additional 10,916 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Spark Therapeutics by 81.6% in the second quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock valued at $1,507,000 after acquiring an additional 11,335 shares during the last quarter. 77.84% of the stock is currently owned by hedge funds and other institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.